The Alaska Permanent Fund Corporation (APFC) is a state-owned sovereign wealth fund that manages and invests Alaska's oil and mineral revenues across public equities, fixed income, private equity, real estate, infrastructure, and other asset classes for the long-term benefit of current and future generations of Alaskans.
60% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $193.5M (across 13 rounds with reported amounts).
Portfolio
10
Fund Size
$91.2B
Top Stage
Series A
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
15 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| KKenai Therapeutics | Series A | $82M | Jan 2024 |
 Repertoire Immune Medicines | Series B | $189M | Apr 2021 |
| Repertoire Immune Medicines | Unknown | $189M | Jan 2021 |
| IIndigo Carbon | Series F | $360M | Jan 2020 |
 Indigo Agriculture | Series F | $500M | Nov 2019 |
| Indigo Agriculture | Series E | — | Sep 2018 |
| Indigo Agriculture | Series D | $203M | Dec 2017 |
 Codiak Biosciences | Series C | $76.5M | Nov 2017 |
| Codiak Biosciences | Series A | $80M | Nov 2015 |
 Denali Therapeutics | Series D | $217M | May 2015 |
 Juno Therapeutics | Series A | $176M | Apr 2014 |
 Sana Biotechnology | Growth | — | — |
| Codiak Biosciences | Series B | $61M | — |
 Kenai | Series A | $82M | — |
 Tessera | Series C | $300M | — |
Top Co-Investors
Flagship Pioneering11 shared
ARCH Venture Partners6 shared
Baillie Gifford4 shared
Alexandria Venture Investments3 shared
Fidelity Investments3 shared
G Squared3 shared
Primary Venture Partners2 shared
F-Prime Capital2 shared
GV2 shared
Altitude Life Science Ventures2 shared
Bezos Expeditions2 shared
Investment Corporation of Dubai2 shared
Activant Capital2 shared
Euclidean Capital2 shared
The Column Group2 shared
The Invus Group, LLC2 shared
Omega Funds1 shared
BECO Capital1 shared
Last updated: 7 October 2026